Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications
Open Access
- 6 January 2025
- Vol. 10 (1) , 104097
Abstract
No abstract availableKeywords
Funding Information
- Korea Health Industry Development Institute
- Ministry of Health and Welfare (HI14C1277)
- Ministry of Education (2020R1A6A1A03047972)
- Ministry of Education (PRJNA1132558)
- National Research Foundation of Korea
This publication has 25 references indexed in Scilit:
- Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue SarcomasJACC: Cardiooncology, 2024
- Immune microenvironment of intimal sarcomas: Adaptive immune resistance with potential therapeutic implicationsAmerican Journal of Clinical Pathology, 2023
- Establishing an RNA fusions panel in soft tissue sarcoma with clinical validationScientific Reports, 2023
- Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targetsNature Communications, 2022
- Clinical genomic profiling in the management of patients with soft tissue and bone sarcomaNature Communications, 2022
- Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunitiesSignal Transduction and Targeted Therapy, 2022
- Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signatureLaboratory Investigation, 2021
- Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma NetworkCancer, 2019
- Pazopanib in advanced soft tissue sarcomasSignal Transduction and Targeted Therapy, 2019
- Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor PalbociclibJAMA Oncology, 2016